Trulicity

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
16-03-2023
Tabia za bidhaa Tabia za bidhaa (SPC)
16-03-2023

Viambatanisho vya kazi:

dulaglutide

Inapatikana kutoka:

Eli Lilly Nederland B.V.

ATC kanuni:

A10BJ05

INN (Jina la Kimataifa):

dulaglutide

Kundi la matibabu:

Drugs used in diabetes, Blood glucose lowering drugs, excl. insulins

Eneo la matibabu:

Diabetes Mellitus, Type 2

Matibabu dalili:

Trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Bidhaa muhtasari:

Revision: 17

Idhini hali ya:

Authorised

Idhini ya tarehe:

2014-11-21

Taarifa za kipeperushi

                                72
B. PACKAGE LEAFLET
73
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
TRULICITY 0.75 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 1.5 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 3 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 4.5 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
dulaglutide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Trulicity is and what it is used for
2.
What you need to know before you use Trulicity
3.
How to use Trulicity
4.
Possible side effects
5.
How to store Trulicity
6.
Contents of the pack and other information
1.
WHAT TRULICITY IS AND WHAT IT IS USED FOR
Trulicity contains an active substance called dulaglutide and is used
to lower blood sugar (glucose) in
adults and children aged 10 years and above, with type 2 diabetes
mellitus and can help prevent heart
disease.
Type 2 diabetes is a condition in which your body does not make enough
insulin, and the insulin that
your body produces does not work as well as it should.
When this happens, sugar (glucose) builds up in the blood.
Trulicity is used:
-
on its own if your blood sugar is not properly controlled by diet and
exercise alone, and you
can’t take metformin (another diabetes medicine).
-
or with other medicines for diabetes when they are not enough to
control your blood sugar
levels. These other medicines may be medicines taken by mouth and/or
insulin given by
injection.
It is important to continue to follow the advice on diet and exercise
given to you by your doctor,
pharmac
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Trulicity 0.75 mg solution for injection in pre-filled pen
Trulicity 1.5 mg solution for injection in pre-filled pen
Trulicity 3 mg solution for injection in pre-filled pen
Trulicity 4.5 mg solution for injection in pre-filled pen
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Trulicity 0.75 mg solution for injection in pre-filled pen
Each pre-filled pen contains 0.75 mg of dulaglutide* in 0.5 ml
solution.
Trulicity 1.5 mg solution for injection in pre-filled pen
Each pre-filled pen contains 1.5 mg of dulaglutide* in 0.5 ml
solution.
Trulicity 3 mg solution for injection in pre-filled pen
Each pre-filled pen contains 3 mg of dulaglutide* in 0.5 ml solution.
Trulicity 4.5 mg solution for injection in pre-filled pen
Each pre-filled pen contains 4.5 mg of dulaglutide* in 0.5 ml
solution.
*produced in CHO cells by recombinant DNA technology.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear, colourless solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Type 2 Diabetes Mellitus
Trulicity is indicated for the treatment of patients 10 years and
above with insufficiently controlled
type 2 diabetes mellitus as an adjunct to diet and exercise
•
as monotherapy when metformin is considered inappropriate due to
intolerance or
contraindications
•
in addition to other medicinal products for the treatment of diabetes.
For study results with respect to combinations, effects on glycaemic
control and cardiovascular events,
and the populations studied, see sections 4.4, 4.5 and 5.1.
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_ _
Posology
_Adults _
_ _
_Monotherapy _
The recommended dose is 0.75 mg once weekly.
_Add-on therapy_
The recommended dose is 1.5 mg once weekly.
If needed,
•
the 1.5 mg dose can be increased after at least 4 weeks to 3 mg once
weekly.
•
the 3 mg dose can be increased after at least 4 weeks to 4.5 mg once
weekly.
The maximum dose is 4.5 mg once weekly.
_Paediatri
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kibulgaria 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kihispania 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kicheki 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kidenmaki 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kijerumani 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kiestonia 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kigiriki 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kifaransa 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kiitaliano 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kilatvia 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kilithuania 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kihungari 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kimalta 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kiholanzi 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kipolandi 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kireno 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kiromania 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kislovakia 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kislovenia 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kifinlandi 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kiswidi 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kinorwe 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 16-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 16-03-2023
Tabia za bidhaa Tabia za bidhaa Kroeshia 16-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 16-03-2023

Tafuta arifu zinazohusiana na bidhaa hii

Tazama historia ya hati